The Private Equity team advised Catalent, Inc., a portfolio company of Novo Holdings, on a refinancing transaction to support continued growth and investments in its business to better support its customers. The refinancing includes a new $4.1 billion equivalent seven-year Term Loan B facility and a $600 million revolving credit facility.
Catalent is a leading global contract development and manufacturing organization (CDMO) championing the missions that help people live better and healthier lives. Every product that Catalent helps develop, manufacture, and launch reflects its commitment to improve health outcomes around the world through its patient-first approach. Catalent provides unparalleled service to pharma, biotech, and consumer health customers, delivering on their missions to transform lives. Catalent tailors end-to-end solutions to meet customers’ needs in all phases of development and manufacturing. With thousands of scientists and technicians and the latest technology platforms at nearly 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually.
The Goodwin team was led by Jennifer Bralower, Chris Steinroeder, and Emily Josef, and included Janet Andolina, John Servidio, Anna Gunning, Hannah Bast, and Michele Eason-Priest.
For more information on the deal, please read the press release.